tiprankstipranks
Advertisement
Advertisement

EIKN Stock Latest News

Eikon Therapeutics reports Q2 EPS ($1.63), consensus ($1.46)
The FlyEikon Therapeutics reports Q2 EPS ($1.63), consensus ($1.46)
9d ago
EIKN
Eikon Therapeutics price target lowered to $4 from $5 at Wedbush
PremiumThe Fly
Eikon Therapeutics price target lowered to $4 from $5 at Wedbush
10d ago
EIKN
Eikon Therapeutics Highlights Q3 2026 Oncology Pipeline Progress
PremiumCompany Announcements
Eikon Therapeutics Highlights Q3 2026 Oncology Pipeline Progress
12d ago
8K
EIKN
Eikon Therapeutics announces dose selection for TeLuRide-006 trial
PremiumThe Fly
Eikon Therapeutics announces dose selection for TeLuRide-006 trial
15d ago
EIKN
Eikon Therapeutics Announces Recent Board Director Resignations
PremiumCompany Announcements
Eikon Therapeutics Announces Recent Board Director Resignations
22d ago
8K
EIKN
Eikon Therapeutics doses first patient in TeLuRide-008 study
PremiumThe FlyEikon Therapeutics doses first patient in TeLuRide-008 study
30d ago
EIKN
EIKN’s TeLuRide-008 Trial: A New Lung Cancer Combo Investors Should Watch
Premium
Company Announcements
EIKN’s TeLuRide-008 Trial: A New Lung Cancer Combo Investors Should Watch
1M ago
EIKN
Eikon Therapeutics to be added to Russell 3000 Index
Premium
The Fly
Eikon Therapeutics to be added to Russell 3000 Index
2M ago
EIKN
PremiumCompany Announcements
Eikon Therapeutics Appoints Ma. Fatima Francisco to Board
3M ago
8K
EIKN
Eikon Therapeutics price target lowered to $32 from $34 at BofA
PremiumThe Fly
Eikon Therapeutics price target lowered to $32 from $34 at BofA
3M ago
EIKN
PremiumCompany Announcements
Eikon Highlights Promising New Clinical Data in Oncology
3M ago
8K
EIKN
Eikon Therapeutics presents data on lead programs at ASCO 2026
PremiumThe Fly
Eikon Therapeutics presents data on lead programs at ASCO 2026
3M ago
EIKN
Eikon Therapeutics price target lowered to $5 from $7 at Wedbush
PremiumThe FlyEikon Therapeutics price target lowered to $5 from $7 at Wedbush
4M ago
EIKN
Premium
Ratings
Analyst Reiterates Buy on Eikon Therapeutics, Maintaining $29 December 2026 Price Target on Emerging Oncology Pipeline
4M ago
EIKN
Premium
Company Announcements
Eikon Therapeutics Highlights Q1 2026 Results and Pipeline
4M ago
8K
EIKN
Opening Day: Generate Biomedicines makes public debut
PremiumThe Fly
Opening Day: Generate Biomedicines makes public debut
6M ago
FPS
SGP
Eikon Therapeutics initiated with an Overweight at Cantor Fitzgerald
PremiumThe Fly
Eikon Therapeutics initiated with an Overweight at Cantor Fitzgerald
6M ago
EIKN
Eikon Therapeutics initiated with a Buy at BofA
PremiumThe Fly
Eikon Therapeutics initiated with a Buy at BofA
6M ago
EIKN
Eikon Therapeutics initiated with an Outperform at Mizuho
PremiumThe Fly
Eikon Therapeutics initiated with an Outperform at Mizuho
6M ago
EIKN
Eikon Therapeutics initiated with an Overweight at JPMorgan
PremiumThe FlyEikon Therapeutics initiated with an Overweight at JPMorgan
6M ago
EIKN
Eikon Therapeutics initiated with an Overweight at Morgan Stanley
Premium
The Fly
Eikon Therapeutics initiated with an Overweight at Morgan Stanley
6M ago
EIKN
Spotify upgraded, First Solar downgraded: Wall Street’s top analyst calls
Premium
The Fly
Spotify upgraded, First Solar downgraded: Wall Street’s top analyst calls
6M ago
AI
ALC

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >